BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bareke H, Akbuga J. Complement system's role in cancer and its therapeutic potential in ovarian cancer. Scand J Immunol 2018;88:e12672. [PMID: 29734524 DOI: 10.1111/sji.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhou K, Arslanturk S, Craig DB, Heath E, Draghici S. Discovery of primary prostate cancer biomarkers using cross cancer learning. Sci Rep 2021;11:10433. [PMID: 34001952 DOI: 10.1038/s41598-021-89789-x] [Reference Citation Analysis]
2 Cedzyński M, Świerzko AS. Components of the Lectin Pathway of Complement in Solid Tumour Cancers. Cancers 2022;14:1543. [DOI: 10.3390/cancers14061543] [Reference Citation Analysis]
3 Riihilä P, Nissinen L, Knuutila J, Rahmati Nezhad P, Viiklepp K, Kähäri VM. Complement System in Cutaneous Squamous Cell Carcinoma. Int J Mol Sci 2019;20:E3550. [PMID: 31331124 DOI: 10.3390/ijms20143550] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
4 Bates M, Spillane CD, Gallagher MF, McCann A, Martin C, Blackshields G, Keegan H, Gubbins L, Brooks R, Brooks D, Selemidis S, O'Toole S, O'Leary JJ. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. PLoS One 2020;15:e0243715. [PMID: 33370338 DOI: 10.1371/journal.pone.0243715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rahmati Nezhad P, Riihilä P, Knuutila JS, Viiklepp K, Peltonen S, Kallajoki M, Meri S, Nissinen L, Kähäri VM. Complement Factor D Is a Novel Biomarker and Putative Therapeutic Target in Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2022;14:305. [PMID: 35053469 DOI: 10.3390/cancers14020305] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Edechi CA, Ikeogu N, Uzonna JE, Myal Y. Regulation of Immunity in Breast Cancer. Cancers (Basel) 2019;11:E1080. [PMID: 31366131 DOI: 10.3390/cancers11081080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
7 Samson JM, Ravindran Menon D, Smith DE, Baird E, Kitano T, Gao D, Tan AC, Fujita M. Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. Chem Biol Interact 2019;314:108822. [PMID: 31580832 DOI: 10.1016/j.cbi.2019.108822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Su KM, Lin TW, Liu LC, Yang YP, Wang ML, Tsai PH, Wang PH, Yu MH, Chang CM, Chang CC. The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis. Int J Mol Sci 2020;21:E2824. [PMID: 32316695 DOI: 10.3390/ijms21082824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Talaat IM, Elemam NM, Saber-ayad M. Complement System: An Immunotherapy Target in Colorectal Cancer. Front Immunol 2022;13:810993. [DOI: 10.3389/fimmu.2022.810993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wang J, Zhang C, He W, Gou X. Effect of m6A RNA Methylation Regulators on Malignant Progression and Prognosis in Renal Clear Cell Carcinoma. Front Oncol 2020;10:3. [PMID: 32038982 DOI: 10.3389/fonc.2020.00003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
11 Kim HS, Kim KM, Lee SB, Kim GR, Han YD, Cho MS, Hur H, Lee KY, Kim NK, Min BS. Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer: Insight into the survival paradox. J Surg Oncol 2019;120:423-30. [PMID: 31134644 DOI: 10.1002/jso.25515] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
12 Kopylov AT, Petrovsky DV, Stepanov AA, Rudnev VR, Malsagova KA, Butkova TV, Zakharova NV, Kostyuk GP, Kulikova LI, Enikeev DV, Potoldykova NV, Kulikov DA, Zulkarnaev AB, Kaysheva AL. Convolutional neural network in proteomics and metabolomics for determination of comorbidity between cancer and schizophrenia. J Biomed Inform 2021;122:103890. [PMID: 34438071 DOI: 10.1016/j.jbi.2021.103890] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]